A Site Management Organization is a company that aggregates clinical research site capacity — typically by acquiring individual research sites, forming management agreements with them, or building a network of affiliated sites — and uses that aggregated capacity to negotiate with sponsors and CROs for study placements at member sites. SMOs exist because clinical research sites often struggle to compete individually for studies against larger institutions, and because the operational and regulatory overhead of running a research site creates pressure for centralized infrastructure.
The SMO model has grown significantly as clinical trial complexity has increased. More technology systems, more regulatory requirements, and more demanding sponsor expectations have pushed many independent sites toward SMO membership as a way to share infrastructure cost and access study portfolios they could not reach independently.
What SMO Membership Provides
SMOs typically provide member sites with: access to pre-negotiated study budgets, reducing the time each site spends on individual contract negotiations; centralized regulatory and IRB support; shared CTMS and EDC licensing costs; training programs for coordinators and PIs; and a business development function that maintains sponsor relationships and routes appropriate studies to member sites based on their therapeutic area focus and capacity.
For a small independent research site running two or three studies per year with limited administrative support, SMO membership can significantly reduce the per-study overhead and provide access to study volume the site could not generate independently. The revenue share the SMO takes in exchange — typically 20 to 40 percent of per-patient revenue — needs to be evaluated against the cost of the services provided.
What SMO Membership Costs Beyond the Revenue Share
Revenue share is the explicit cost of SMO membership. The less visible cost is operational control. SMOs typically standardize procedures across their networks — for good operational reasons — which means individual sites operate within protocols set by the network rather than developing their own. Sites that want to build differentiated capabilities, including proprietary physician outreach programs, may find SMO requirements constraining.
SMOs also control sponsor relationships. Member sites receive studies through the SMO's business development function, which means the SMO decides which studies are offered to which sites. A site that wants to build direct relationships with sponsors and CROs may find that SMO membership consolidates those relationships at the network level rather than the site level.
When Building Independent Capability Makes More Sense
Sites that have the coordinator capacity, regulatory infrastructure, and physician outreach capability to compete independently for studies often generate higher per-study revenue by keeping the full per-patient fee rather than sharing it with an SMO. The investment required to build those capabilities — primarily in physician outreach infrastructure, CTMS licensing, and coordinator training — is typically recouped within two to three studies at full per-patient revenue.
The decision between SMO membership and independent operation comes down to whether the site can generate adequate study volume independently. Sites that can — because they have strong enrollment infrastructure and documented CRO relationships — generally earn more by staying independent. Sites that cannot reliably generate study volume on their own may find that SMO membership is the more economically rational choice.